7 results about "GnRH Antagonist" patented technology

The present invention relates to the field of GnRH antagonists and anti-GnRH ligands. The invention also relates to the fields of pharmacy and diagnosis. In particular, the present disclosure relates to the field of contraception and GnRH-related diseases.

The present invention relates to the field of mammalian reproduction and use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

The present invention relates to the field of mammalian reproduction. Disclosed is use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

The invention relates to an oral dosage unit for use in a method of contraception in a human male, said oral dosage units containing GnRH antagonist and dehydroepiandrosterone (DHEA), the method comprising once daily oral administration of the oral dosage unit to the human male during a period of at least 7 days. This contraceptive method is convenient, effectively suppresses spermatogenesis and is reversible. Another aspect of the invention relates to a dosage unit comprising: • GnRH antagonist selected from: o 50-250 mg relugolix; o 167-833 mg linzagolix; o 113-583 mg elagolix; • 100-800 mg dehydroepiandrosterone.

The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a population of female mammals, and / or for fixed-time reproductive management protocols such as oocyte collection protocols, embryo collection protocols, artificial insemination protocols or embryo transfer protocols. Also described are devices and kits for reproductive management, comprising a GnRH antagonist and optionally one or more additional drugs useful for reproductive management.

The present invention relates to a composition comprising at least one GnRH antagonist for use in reducing the risk of recurrent acute urinary retention (AUR) in males of least 45 years of age presenting with a first episode of AUR. Said composition can within four week effectively alleviate urethral obstruction caused by an enlarged prostate, and restore normal urine flow without the need for surgery.

The present invention generally relates to the field of GnRH antagonist formulations. More particularly, the invention relates to pharmaceutical compositions made of microparticles for the slow release of a GnRH antagonist, such as degarelix, medical uses of such pharmaceutical compositions, a kit including such pharmaceutical compositions and methods for the preparation of such pharmaceutical compositions.